VanEck Biotech ETF $BBH Shares Purchased by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. increased its holdings in shares of VanEck Biotech ETF (NASDAQ:BBH) by 40,463.3% in the fourth quarter, Holdings Channel reports. The firm owned 494,061 shares of the company’s stock after buying an additional 492,843 shares during the period. Northwestern Mutual Wealth Management Co. owned about 0.25% of VanEck Biotech ETF worth $93,506,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BBH. Flagship Harbor Advisors LLC acquired a new stake in shares of VanEck Biotech ETF during the 4th quarter worth about $47,000. Allworth Financial LP grew its position in VanEck Biotech ETF by 255.0% in the 4th quarter. Allworth Financial LP now owns 426 shares of the company’s stock valued at $81,000 after acquiring an additional 306 shares in the last quarter. Cibc World Market Inc. acquired a new position in VanEck Biotech ETF in the 3rd quarter valued at about $204,000. Focus Financial Network Inc. acquired a new position in VanEck Biotech ETF in the 4th quarter valued at about $206,000. Finally, GSA Capital Partners LLP acquired a new position in VanEck Biotech ETF in the 3rd quarter valued at about $207,000. 32.05% of the stock is owned by institutional investors and hedge funds.

VanEck Biotech ETF Stock Down 2.3%

NASDAQ BBH opened at $181.78 on Friday. The stock has a 50-day moving average of $187.28 and a two-hundred day moving average of $190.42. VanEck Biotech ETF has a 1-year low of $143.37 and a 1-year high of $202.91.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.